BMS earmarks $100M of its $300M equity pledge for diverse clinical trial investigators

Following its August 2020 pledge to allocate $300 million over the next five years to diversity initiatives, Bristol Myers Squibb announced that $100 million of that will go towards building a program to train 250 new clinical trial investigators from racially and ethnically diverse backgrounds. The decision was propelled by an increased focus on diversity within vaccine trial programs, such as with COVID-19, in order to ensure efficacy in wide-ranging populations. The program will begin accepting applications in January 2021, with candidates for the two-year program chosen by September.

READ THE STORY at FiercePharma »